Stealth Biotherapeutics Inc., of Newton, Mass., presented results from the phase I PREVIEW trial testing elamipretide (formerly Bendavia) in heart failure patients with reduced ejection fraction, showing that the drug appeared safe and well tolerated with demonstrated improvements in key secondary efficacy measures.